-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

134 Prevalence and Impact of COVID-19 in Young Women of Reproductive Age [18-44 Years] Hospitalized with Pulmonary Embolism in the US in 2020 Using National Inpatient Sample Dataset, in-Hospital Mortality, Racial Disparity and Predictors of Mortality

Program: Oral and Poster Abstracts
Type: Oral
Session: 904. Outcomes Research – Non-Malignant Conditions: Across the Age Spectrum: Thromboembolism Outcomes in Adult and Pediatric Patients
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, health disparities research, Diseases
Saturday, December 9, 2023: 9:45 AM

Ummul Z Asfeen, DO1*, Kanishka Uttam Chandani, MD2*, Kalaivani Babu3*, Maithri Vallabhaneni, MBBS4*, Pratiksha Shankarlal Nathani, MBBS5*, Beenish Najam, MBBS6*, Sai Gautham Kanagala, MBBS7*, Srinishant Rajarajan, MBBS3*, Zainab Muslehuddin, MD8*, Taherunnisa Rida9*, Akhil Jain, MD10* and Rupak Desai, MBBS11*

1New York Medical College - Saint Michael's Medical Center, Harrison, NJ
2New York Medical College, Landmark Medical Center, Cumberland, RI
3Sri Ramachandra Medical College and Research Institute, Chennai, India
4Baton Rouge General Medical Center, Baton Rouge
5Vilasrao Deshmukh Government Medical College, Latur, India
6Karachi Medical and Dental College, Karachi, Pakistan
7Internal Medicine, Metropolitan Hospital Center, New York, NY
8Sinai Grace Hospital, Wayne State University, Detroit Medical Center, West Bloomfield, MI
9University Of Texas at Dallas, Richardson, TX
10Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
11Independent Researcher, Outcomes Research, Atlanta, GA

Title: Prevalence and Impact of COVID -19 on In-hospital Outcomes and Associated Racial Disparities in Young Women of Reproductive Age Group (18-44 years) Hospitalized with Pulmonary Embolism in the US in 2020


Given the potential of thrombotic events such as pulmonary embolism in COVID-19, it is essential to comprehend the specific risks and effects on young women of reproductive age, a high-risk group for venous thromboembolism. There is a paucity of data regarding the prevalence and impact of COVID-19 in young women within the reproductive age group who were hospitalized with pulmonary embolism (PE) in the United States during the year 2020.


Utilizing the National Inpatient Sample (NIS) 2020 and relevant ICD-10-CM codes, we identified admissions for PE with COVID-19 vs. without COVID-19 among Young Women [18–44 years] hospitalized with PE. We compared the baseline characteristics and comorbidities between the two groups with and without COVID-19. Furthermore, we analyzed the multivariable adjusted odds ratio (OR) of all-cause mortality in COVID-19 with the non-COVID-19 cohort as a referent, subgroup odds for white vs. other races, and effect modification by diabetes mellitus (DM) as a comorbidity.


We identified 34,730 hospitalizations in young female patients of the reproductive age group (18 to 44 years) in 2020 with the diagnosis of PE, of which 2345 (6.8%) had COVID-19. The prevalence of PE was higher in COVID-19 cohort (1.6% vs. 0.6%, p<0.001). The majority of the patients with PE were Caucasian (58.9%) and in the lowest median income quartile (36.9%). Analysis of various comorbidities in both cohorts revealed a statistically significant higher prevalence of hypertension (29.6% in those with COVID-19 vs. 24.3% in those without COVID-19, p <0.001), Similarly, hyperlipidemia (11.7% vs. 7.3%, p <0.001), DM (20.9% vs. 12.4%, p <0.001), and obesity (50.3% vs. 32.7%, p <0.001), were more prevalent in COVID-19, indicating that patients who were admitted with PE with concomitant COVID-19 were of poorer overall cardiovascular health than those with COVID-19. Unadjusted all-cause mortality odds ratio was 2.41 (1.71-3.38, p <0.001) in PE with COVID-19 than non-COVID-19. Adjusted all-cause mortality for demographics, hospital level covariates, and pre-existing conditions revealed similar statistically significant findings, with the odds ratio being 2.8 (1.94-4.04, p <0.001). There was no racial disparity observed in all-cause mortality for non-whites compared to white patients admitted with PE and COVID-19 (p=0.064). Furthermore, all-cause mortality in patients with COVID-19 and PE was found to have an odds ratio of 3.04 (1.05-8.81, p=0.041) in a subset of DM compared to non-DM. The results have confirmed a further robust positive association with increasing mortality risk with DM in young women hospitalized with PE and COVID-19.

Conclusion and Relevance:

There was a nearly three times higher prevalence of PE and 2.5 times higher odds of mortality in Young Women of Reproductive age [18–44 years] hospitalized with PE with COVID-19 as compared to without COVID-19. The effect of PE and a higher risk of mortality are already established with COVID-19; however, there is a paucity of data in young women, which warrants more prospective studies to evaluate the long-term thromboembolic risks of PE and associated events in this population. The findings of this research could have significant implications for understanding the relationship between COVID-19 and PE in this patient population. Special emphasis needs to be laid on improved healthcare strategies, targeted interventions, and patient education in this cohort to establish future research agendas and provide better health care outcomes for this vulnerable group with established risk factors like diabetes.

Key Words: COVID-19, Young Women, Pulmonary Embolism, In-Hospital Mortality, Racial Disparity, Predictors of Mortality, Diabetes Mellitus, National Inpatient Sample

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH